.jpg?format=webp&width=780)
The study 676 scleroderma cancer cases and 687 scleroderma controls without cancer. Anti-POLR3 and monospecific anti-Ro52 were linked to increased overall cancer risk, while anti-centromere and anti-U1RNP were associated with lower risk. These immune responses also influenced the risk of cancer-associated scleroderma. Combining certain antibodies showed the potential in decreasing cancer risk. The findings suggest that specific scleroderma immune responses could help identify cancer risk among patients.
Like
Save
Share